NANO Nanoco Group Plc

TIDMNANO

RNS Number : 2270Q

Nanoco Group PLC

08 September 2017

NANOCO GROUP PLC

("Nanoco" or the "Company")

Commercial Supply and License Agreement in the Medical Devices Sector

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, today announces that it has signed a Commercial Supply and License Agreement with a US corporation in the field of medical devices.

Nanoco will supply film product and other technologies for light therapy products for the treatment of pain, soft tissue injury and dermatologic conditions such as acne and skin anti-aging.

Nanoco continues to develop in Life Sciences as one of its target markets and, as recently announced, the Life Sciences division has made further progress in in-vivo optical imaging, diagnosis and targeted therapy of cancer, being awarded an Innovate UK Grant for a VIVODOTS TM programme in conjunction with University College London targeting pancreatic cancer.

This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 ("MAR"). Upon the publication of this announcement, this inside information is now considered to be in the public domain. The Board note the recent decline in the Company share price and confirm there has been no change in the financial position of the Company since the Company update on 25 August 2017 and following this announcement there is no price sensitive information not in the market.

For further information, please contact:

Nanoco Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

David Blain, Chief Financial Officer

Caroline Watson, Investor Relations Manager Tel: + 44 (0) 7799 897357

cwatson@nanocotechnologies.com

Peel Hunt

Tel: +44 (0) 20 7418 8900

Adrian Trimmings

George Sellar

MHP Communications Tel: +44 (0) 20 3128 8570

Reg Hoare / Andrew Leach / Giles Robinson / Pete Lambie

nanoco@mhpc.com

Notes for editors:

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, Nanoco has non-exclusive manufacturing and marketing licensing agreements with The Dow Chemical Company, Merck KGaA and Taiwan's Wah Hong Industrial Corporation. Nanoco also has a strategy of direct sales in display and in its other target markets, including lighting.

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRKVLBBDKFLBBK

(END) Dow Jones Newswires

September 08, 2017 05:34 ET (09:34 GMT)

Nanoco (LSE:NANO)
Historical Stock Chart
From Apr 2024 to May 2024

Nanoco (LSE:NANO)
Historical Stock Chart
From May 2023 to May 2024